PriceTargets.com logo

NASDAQ:OGI - OrganiGram Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $2.64
  • Forecasted Upside: 62.23 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 8 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.63 As of 01/25/2021 01:00 AM ET
▼ -0.09 (-5.23%)
1 month | 3 months | 12 months
Get New OrganiGram Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OGI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OGI

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$2.64
▲ +62.23% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for OrganiGram in the last 3 months. The average price target is $2.64, with a high forecast of $4.00 and a low forecast of $1.72. The average price target represents a 62.23% upside from the last price of $1.63.
Hold
The current consensus among 12 polled investment analysts is to hold stock in OrganiGram. This rating has held steady since January 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/4/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 8 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/13/2021Alliance Global PartnersDowngradeBuy ➝ NeutralMedium
i
Rating by A. Grey at Alliance Global Partners
1/12/2021Canaccord GenuityDowngradeBuy ➝ Hold$2.50 ➝ $2.00High
i
1/12/2021Raymond JamesUpgradeMarket Perform ➝ OutperformHigh
i
12/4/2020Cantor FitzgeraldLower Price TargetOverweight$5.35 ➝ $3.00High
i
12/1/2020CIBCBoost Price TargetNeutral$2.00 ➝ $2.25High
i
12/1/2020Canaccord GenuityReiterated RatingBuyHigh
i
9/17/2020Cantor FitzgeraldReiterated RatingBuy$5.35Medium
i
8/10/2020Jefferies Financial GroupReiterated RatingBuy$3.79High
i
7/22/2020CIBCLower Price TargetNeutral$2.75 ➝ $2.00High
i
7/22/2020Canaccord GenuityLower Price TargetBuy$5.00 ➝ $3.00Low
i
7/22/2020Stifel NicolausDowngradeBuy ➝ Hold$1.75Medium
i
7/21/2020Pi FinancialReiterated RatingBuyMedium
i
Rating by J. Zandberg at Pi Financial
7/21/2020AltaCorp CapitalDowngradeOutperform ➝ Sector PerformHigh
i
Rating by D. Kideckel at AltaCorp Capital
7/21/2020OppenheimerReiterated RatingHoldHigh
i
Rating by Rupesh Parikh at Oppenheimer Holdings Inc.
7/7/2020Alliance Global PartnersInitiated CoverageBuy$4.00Medium
i
Rating by A. Grey at Alliance Global Partners
6/29/2020Raymond JamesDowngradeOutperform ➝ Market PerformMedium
i
Rating by Rahul Sarugaser at Raymond James
6/16/2020OppenheimerInitiated CoverageHoldMedium
i
Rating by Rupesh Parikh at Oppenheimer Holdings Inc.
5/29/2020Raymond JamesReiterated RatingBuyMedium
i
Rating by Rahul Sarugaser at Raymond James
4/15/2020CIBCDowngradeOutperform ➝ Neutral$5.00 ➝ $2.75Low
i
4/14/2020AltaCorp CapitalUpgradeSector Perform ➝ OutperformLow
i
Rating by D. Kideckel at AltaCorp Capital
4/14/2020Cantor FitzgeraldLower Price TargetOverweight$5.80 ➝ $5.60Low
i
Rating by P. Zuanic at Cantor Fitzgerald
4/1/2020Cantor FitzgeraldLower Price TargetOverweight$9.00 ➝ $5.80High
i
Rating by P. Zuanic at Cantor Fitzgerald
3/19/2020Bank of AmericaUpgradeHold$1.72High
i
Rating by Christopher Carey at Bank of America Co.
3/19/2020CitigroupUpgradeUnderperform ➝ NeutralMedium
i
1/15/2020Raymond JamesUpgradeMarket Perform ➝ OutperformHigh
i
Rating by Rahul Sarugaser at Raymond James
1/13/2020Bank of AmericaInitiated CoverageUnderperformHigh
i
1/8/2020Raymond JamesDowngradeOutperform ➝ Market PerformLow
i
Rating by Rahul Sarugaser at Raymond James
11/26/2019AltaCorp CapitalDowngradeOutperform ➝ Sector PerformLow
i
Rating by D. Kideckel at AltaCorp Capital
11/25/2019Beacon SecuritiesDowngradeBuy ➝ HoldHigh
i
Rating by R. Stanley at Beacon Securities
11/12/2019BMO Capital MarketsDowngradeOutperform ➝ Market PerformHigh
i
11/5/2019Cantor FitzgeraldInitiated CoverageOverweight$17.10High
i
Rating by P. Zuanic at Cantor Fitzgerald
10/17/2019Paradigm CapitalSet Price TargetBuy$8.50Low
i
Rating by Corey Hammill at Paradigm Capital
10/11/2019Jefferies Financial GroupUpgradeHold ➝ Buy$8.20High
i
9/24/2019CIBCInitiated CoverageOutperformer$9.00High
i
9/18/2019Raymond JamesInitiated CoverageBuyLow
i
Rating by Rahul Sarugaser at Raymond James
9/5/2019OppenheimerInitiated CoverageMarket PerformHigh
i
7/15/2019Pi FinancialSet Price TargetBuy$12.00High
i
Rating by Jason Zandberg at Pi Financial
5/3/2019Jefferies Financial GroupDowngradeBuy ➝ HoldLow
i
4/17/2019Paradigm CapitalInitiated CoverageBuyLow
i
Rating by Rahul Sarugaser at Paradigm Capital
2/25/2019Jefferies Financial GroupInitiated CoverageBuyLow
i
(Data available from 1/26/2016 forward)
OrganiGram logo
Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers cannabis flowers, extracts, edibles and oils, beverages, and other cannabis products for adult recreational market under the Edison Reserve, Edison Cannabis Co., ANKR Organics, and Trailblazer brands; and medical cannabis products, including strains, cannabis oils, extracts, edibles, beverages, and vaporizers for the medical market. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.
Read More

Today's Range

Now: $1.63
$1.61
$1.79

50 Day Range

MA: $1.53
$1.29
$1.83

52 Week Range

Now: $1.63
$1.01
$2.85

Volume

14,286,197 shs

Average Volume

14,369,607 shs

Market Capitalization

$378.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.3

Frequently Asked Questions

What sell-side analysts currently cover shares of OrganiGram?

The following Wall Street sell-side analysts have issued reports on OrganiGram in the last twelve months: Alliance Global Partners, AltaCorp Capital, Bank of America Co., Canaccord Genuity, Cantor Fitzgerald, CIBC, Citigroup Inc., Jefferies Financial Group Inc., Oppenheimer Holdings Inc., Pi Financial, Raymond James, Stifel Nicolaus, and Zacks Investment Research.

What is the current price target for OrganiGram?

7 Wall Street analysts have set twelve-month price targets for OrganiGram in the last year. Their average twelve-month price target is $2.64, suggesting a possible upside of 58.8%. Alliance Global Partners has the highest price target set, predicting OGI will reach $4.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $1.72 for OrganiGram in the next year.

What is the current consensus analyst rating for OrganiGram?

OrganiGram currently has 8 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in OGI, but not buy more shares or sell existing shares.

What other companies compete with OrganiGram?

Other companies that are similar to OrganiGram include Endo International, Supernus Pharmaceuticals, Ocular Therapeutix, Amneal Pharmaceuticals, Zealand Pharma A/S, Cytokinetics, ImmunoGen, Travere Therapeutics, Travere Therapeutics, DiaMedica Therapeutics, Repare Therapeutics, Applied Molecular Transport, Mersana Therapeutics, Keros Therapeutics and Trillium Therapeutics.

How do I contact OrganiGram's investor relations team?

OrganiGram's physical mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company's listed phone number is 1-855-961-9420. The official website for OrganiGram is www.organigram.ca.